Collagen turnover biomarkers to predict outcome of patients with biliary cancer
Abstract Background The collagen-rich tumor stroma plays a crucial role in biliary tract cancer (BTC). Collagen biomarkers of type I collagen (reC1M), type III collagen (PRO-C3), type IV collagen (C4G), type VIII collagen (PRO-C8), type XI collagen (PRO-C11), type XVII collagen (PRO-C17) and type VI...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03645-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862210287370240 |
|---|---|
| author | Leonard Kaps Muhammed A. Genc Markus Moehler Stephan Grabbe Jörn M. Schattenberg Detlef Schuppan Rasmus Sund Pedersen Morten A. Karsdal Philipp Mildenberger Annett Maderer Nicholas Willumsen |
| author_facet | Leonard Kaps Muhammed A. Genc Markus Moehler Stephan Grabbe Jörn M. Schattenberg Detlef Schuppan Rasmus Sund Pedersen Morten A. Karsdal Philipp Mildenberger Annett Maderer Nicholas Willumsen |
| author_sort | Leonard Kaps |
| collection | DOAJ |
| description | Abstract Background The collagen-rich tumor stroma plays a crucial role in biliary tract cancer (BTC). Collagen biomarkers of type I collagen (reC1M), type III collagen (PRO-C3), type IV collagen (C4G), type VIII collagen (PRO-C8), type XI collagen (PRO-C11), type XVII collagen (PRO-C17) and type VIII collagen (TUM) may be used as potential non-invasive biomarkers. Methods We measured the seven biomarkers of collagen turnover in sera of 72 patients with BTC at baseline and after first and second chemotherapy cycle (CTX). Markers were also assessed in sera of 50 healthy controls and compared to levels of patients at baseline. The diagnostic and prognostic value of the markers was evaluated for overall survival (OS) and progression-free survival (PFS). Results Patients had a median age of 65 years (IQR 57–70), while healthy controls were younger, with a median age of 46 years (IQR 38–54). The majority of patients (62%) were diagnosed with intrahepatic bile duct adenocarcinoma. Except C4G, all collagen turnover markers were significantly (p < 0.001) increased in serum from patients with BTC compared to healthy controls. PRO-C3 was the best marker to discriminate between patients with BTC and controls, reaching an area under a receiver operating characteristic (AUROC) of 0.98 (95% CI 0.95; 0.99) with a sensitivity (92%) and specificity (94%) balanced cutoff of 77.3 ng/ml. Patients with high levels (cohort separated by median split) of PRO-C8 (HR 2.85, 95% CI 1.42; 5.73) followed by C3M (HR 2.33, 95% CI 1.2; 4.5), PRO-C3 (HR 3.09, 95% CI 1.5; 6.36) and CA 19–9 (HR 2.52, 95% CI 1.37; 4.64) as reference biomarker had a shorter OS. Notably, only the novel marker PRO-C8 was also predictive of PFS (HR 3.26, 95% CI 1.53; 6.95). Associations with survival outcomes remained significant after adjusting for relevant risk factors (CA 19–9 and CEA at baseline, age, presence of metastases, weight, height and gender). Conclusion The collagen turnover markers PRO-C8, C3M, PRO-C3 and the established biomarker CA 19–9 were prognostic for OS in patients with BTC while only PRO-C8 was also predictive for PFS. PRO-C3 showed the best diagnostic performance to discriminate between patients with BTC and controls. Trial registration Trial registration number and date of registration NCT00661830 (NCT number) 15 April 2008 Trial registry The complete registry can found under: https://clinicaltrials.gov/study/NCT00661830?tab=table#administrative-information (last accessed 01/2025) Principal investigator and study sponsor Markus Moehler, MD Johannes Gutenberg University Mainz |
| format | Article |
| id | doaj-art-9c41629946164b48865879af38d42fa4 |
| institution | Kabale University |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-9c41629946164b48865879af38d42fa42025-02-09T12:39:37ZengBMCBMC Gastroenterology1471-230X2025-02-0125111410.1186/s12876-025-03645-0Collagen turnover biomarkers to predict outcome of patients with biliary cancerLeonard Kaps0Muhammed A. Genc1Markus Moehler2Stephan Grabbe3Jörn M. Schattenberg4Detlef Schuppan5Rasmus Sund Pedersen6Morten A. Karsdal7Philipp Mildenberger8Annett Maderer9Nicholas Willumsen10Department of Dermatology, University Medical Center of the Johannes Gutenberg-UniversityFirst Department of Medicine, University Medical Center of the Johannes-Gutenberg UniversityFirst Department of Medicine, University Medical Center of the Johannes-Gutenberg UniversityDepartment of Dermatology, University Medical Center of the Johannes Gutenberg-UniversityDepartment of Medicine II, Saarland University Medical Center, Saarland UniversityUniversity Medical Center, Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg-UniversityNordic Bioscience A/SNordic Bioscience A/SInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg UniversityFirst Department of Medicine, University Medical Center of the Johannes-Gutenberg UniversityNordic Bioscience A/SAbstract Background The collagen-rich tumor stroma plays a crucial role in biliary tract cancer (BTC). Collagen biomarkers of type I collagen (reC1M), type III collagen (PRO-C3), type IV collagen (C4G), type VIII collagen (PRO-C8), type XI collagen (PRO-C11), type XVII collagen (PRO-C17) and type VIII collagen (TUM) may be used as potential non-invasive biomarkers. Methods We measured the seven biomarkers of collagen turnover in sera of 72 patients with BTC at baseline and after first and second chemotherapy cycle (CTX). Markers were also assessed in sera of 50 healthy controls and compared to levels of patients at baseline. The diagnostic and prognostic value of the markers was evaluated for overall survival (OS) and progression-free survival (PFS). Results Patients had a median age of 65 years (IQR 57–70), while healthy controls were younger, with a median age of 46 years (IQR 38–54). The majority of patients (62%) were diagnosed with intrahepatic bile duct adenocarcinoma. Except C4G, all collagen turnover markers were significantly (p < 0.001) increased in serum from patients with BTC compared to healthy controls. PRO-C3 was the best marker to discriminate between patients with BTC and controls, reaching an area under a receiver operating characteristic (AUROC) of 0.98 (95% CI 0.95; 0.99) with a sensitivity (92%) and specificity (94%) balanced cutoff of 77.3 ng/ml. Patients with high levels (cohort separated by median split) of PRO-C8 (HR 2.85, 95% CI 1.42; 5.73) followed by C3M (HR 2.33, 95% CI 1.2; 4.5), PRO-C3 (HR 3.09, 95% CI 1.5; 6.36) and CA 19–9 (HR 2.52, 95% CI 1.37; 4.64) as reference biomarker had a shorter OS. Notably, only the novel marker PRO-C8 was also predictive of PFS (HR 3.26, 95% CI 1.53; 6.95). Associations with survival outcomes remained significant after adjusting for relevant risk factors (CA 19–9 and CEA at baseline, age, presence of metastases, weight, height and gender). Conclusion The collagen turnover markers PRO-C8, C3M, PRO-C3 and the established biomarker CA 19–9 were prognostic for OS in patients with BTC while only PRO-C8 was also predictive for PFS. PRO-C3 showed the best diagnostic performance to discriminate between patients with BTC and controls. Trial registration Trial registration number and date of registration NCT00661830 (NCT number) 15 April 2008 Trial registry The complete registry can found under: https://clinicaltrials.gov/study/NCT00661830?tab=table#administrative-information (last accessed 01/2025) Principal investigator and study sponsor Markus Moehler, MD Johannes Gutenberg University Mainzhttps://doi.org/10.1186/s12876-025-03645-0Tumor markerExtracellular matrixGastrointestinal cancer |
| spellingShingle | Leonard Kaps Muhammed A. Genc Markus Moehler Stephan Grabbe Jörn M. Schattenberg Detlef Schuppan Rasmus Sund Pedersen Morten A. Karsdal Philipp Mildenberger Annett Maderer Nicholas Willumsen Collagen turnover biomarkers to predict outcome of patients with biliary cancer BMC Gastroenterology Tumor marker Extracellular matrix Gastrointestinal cancer |
| title | Collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| title_full | Collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| title_fullStr | Collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| title_full_unstemmed | Collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| title_short | Collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| title_sort | collagen turnover biomarkers to predict outcome of patients with biliary cancer |
| topic | Tumor marker Extracellular matrix Gastrointestinal cancer |
| url | https://doi.org/10.1186/s12876-025-03645-0 |
| work_keys_str_mv | AT leonardkaps collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT muhammedagenc collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT markusmoehler collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT stephangrabbe collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT jornmschattenberg collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT detlefschuppan collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT rasmussundpedersen collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT mortenakarsdal collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT philippmildenberger collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT annettmaderer collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer AT nicholaswillumsen collagenturnoverbiomarkerstopredictoutcomeofpatientswithbiliarycancer |